Artemis Therapeutics (OTCMKTS:ATMS) and GlyEco (OTCMKTS:GLYE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.
This table compares Artemis Therapeutics and GlyEco’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Artemis Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, GlyEco has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.
Insider & Institutional Ownership
29.2% of GlyEco shares are held by institutional investors. 7.5% of Artemis Therapeutics shares are held by insiders. Comparatively, 22.1% of GlyEco shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Artemis Therapeutics and GlyEco’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Artemis Therapeutics||N/A||N/A||-$1.14 million||N/A||N/A|
|GlyEco||$12.07 million||0.25||-$5.18 million||N/A||N/A|
Artemis Therapeutics has higher earnings, but lower revenue than GlyEco.
This is a summary of current ratings and recommmendations for Artemis Therapeutics and GlyEco, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
GlyEco beats Artemis Therapeutics on 6 of the 8 factors compared between the two stocks.
About Artemis Therapeutics
Artemis Therapeutics Inc., a biopharmaceutical company, engages in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company's lead product candidate is Artemisone, an orally-administered 10-alpha-amino artemisinin derivative with antiviral and antiparasitic properties. It focuses on advancing Artemisone as an antiparasitic treatment for patients infected with Plasmodium falciparum; and as an antiviral agent to address unmet clinical needs in immunocompromised patients infected with human cytomegalovirus and other viral or infectious diseases. The company has license agreement with Hadasit Medical Research Services and Development Ltd., Hadassah Medical Organization, and Hong Kong University of Science and Technology R and D Corporation Limited for the development of Artemisone. Artemis Therapeutics Inc. was incorporated in 1997 and is based in New York, New York. Artemis Therapeutics Inc. is a subsidiary of Tonak Ltd.
GlyEco, Inc., a specialty chemical company, develops, manufactures, and distributes performance fluids for the automotive, commercial, and industrial markets in North America. The company operates through two segments, Consumer and Industrial. Its Consumer segment provides antifreeze/coolant products; heating, ventilation, and air conditioning fluids; and waste glycol disposal services. The company's Industrial segment develops, manufactures, and markets additive packages for the antifreeze/coolant, gas patch coolant, and heat transfer industries; and METALGUARD additive package product line comprising one-step inhibitor systems to make various types of antifreeze concentrates and 50/50 coolants for automobiles, heavy-duty diesel engines, stationary engines in gas patch, and other applications, as well as METALGUARD heat transfer fluids that include propylene and ethylene glycol based light and heavy-duty fluids for various operating temperatures. It also operates a glycol re-distillation plant in West Virginia, which processes waste glycol into virgin quality recycled glycol for sale to industrial customers. GlyEco, Inc. was founded in 1996 and is based in Rock Hill, South Carolina.
Receive News & Ratings for Artemis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artemis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.